Results 71 to 80 of about 172,168 (267)

Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia

open access: yesBiotechnology Progress, EarlyView.
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng   +6 more
wiley   +1 more source

Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]

open access: yesJournal of Lipid Research, 2013
Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns   +9 more
doaj   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo   +10 more
wiley   +1 more source

Extracellular vesicles derived from edible plants and edible fungi: Compositional characteristics, engineering strategies and biofunctions

open access: yesFood Biomacromolecules, EarlyView.
Non‐animal extracellular vesicles as bioactive‐compound carriers: compositional characteristics, engineering strategies, and biofunctions. Abstract Animal‐derived extracellular vesicles (EVs) were widely used for bioactive compound delivery but constrained by complex origins, potential immunogenicity, and pathogen contamination.
Jiahao Yu   +6 more
wiley   +1 more source

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

open access: yes, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G.   +24 more
core   +1 more source

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells

open access: yesBMC Cancer, 2011
Background The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of ...
Chai Juin Hsien   +5 more
doaj   +1 more source

Cross‐Platform Comparison of Chemoproteomics Workflows: Orbitrap‐TMT Versus timsTOF‐diaPASEF

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Chemoproteomics aims to achieve precise and comprehensive quantification of protein–small molecule interactions, yet methodological comparisons across quantitative proteomics workflows remain scarce. Here, we systematically benchmark tandem mass tag data‐dependent acquisition (TMT‐DDA) on Orbitrap Exploris/Eclipse instruments against label ...
Ursula M. Glocker   +7 more
wiley   +1 more source

The regulation of bcr-abl in hypoxia is through the mTOR pathway

open access: yes, 2020
Chronic myeloid leukemia (CML) is usually characterized by the formation of the fusion onco-protein bcr-abl. Therefore, the majority of CML treatments are bcr-abl specific tyrosine kinase inhibitors (TKIs).
Di Trapani, Giovanna   +5 more
core   +1 more source

Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases

open access: yesJournal of Experimental & Clinical Cancer Research, 2018
Background The bcr-abl fusion gene is the pathological origin of chronic myeloid leukemia (CML) and plays a critical role in the resistance of imatinib. Thus, bcr-abl disruption-based novel therapeutic strategy may warrant exploration.
Ningshu Huang   +8 more
doaj   +1 more source

Neue Ansätze des molekularen Targetings bei der Philadelphia-Chromosom-positiven Leukämie [PDF]

open access: yes, 2011
In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the constitutive activation of multiple signaling pathways down-stream to the ...
Mian, Afsar Ali
core  

Home - About - Disclaimer - Privacy